Unraveling the Role of Cancer-associated Fibroblasts in B Cell Lymphoma

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Nov 18

PMID 39555055

Authors

Prithviraj Mukherjee

Stephen M Ansell

Patrizia Mondello

Affiliations

Soon will be listed here.

Abstract

Recent breakthroughs in research have sparked a paradigm shift in our understanding of cancer biology, uncovering the critical role of the crosstalk between tumor cells and the immune cells of the tumor microenvironment (TME) in malignant transformation. Fibroblasts have long been viewed as ancillary participants in cancer progression, often eclipsed by the prominence given to malignant cells. Novel investigations, however, have increasingly acknowledged the essential part played by the fibroblasts and their phenotypic doppelganger cancer-associated fibroblasts (CAFs) in fostering immunosuppression and promoting tumor progression. Here we review the cell-of-origin from which CAFs derive and their altered programs compared to their normal counterpart. We will also discuss the complex interplay between CAFs and the surrounding immune cells of the TME in the context of solid tumors and B cell lymphomas, with a focus on the "reprogrammable" role of CAFs in immunosuppression, immuno-activation and immuno-avoidance, and their implications on drug resistance. Finally, we will examine the existing and plausible therapeutic approaches targeting CAFs as a strategy to enhance treatment response.

References

Hilmi M, Nicolle R, Bousquet C, Neuzillet C . Cancer-Associated Fibroblasts: Accomplices in the Tumor Immune Evasion. Cancers (Basel). 2020; 12(10). PMC: 7602282. DOI: 10.3390/cancers12102969. View

Malhotra D, Fletcher A, Astarita J, Lukacs-Kornek V, Tayalia P, F Gonzalez S . Transcriptional profiling of stroma from inflamed and resting lymph nodes defines immunological hallmarks. Nat Immunol. 2012; 13(5):499-510. PMC: 3366863. DOI: 10.1038/ni.2262. View

Cha S, Qin H, Kannan S, Rawal S, Watkins L, Baio F . Nonstereotyped lymphoma B cell receptors recognize vimentin as a shared autoantigen. J Immunol. 2013; 190(9):4887-98. PMC: 3633696. DOI: 10.4049/jimmunol.1300179. View

Apollonio B, Spada F, Petrov N, Cozzetto D, Papazoglou D, Jarvis P . Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma. J Clin Invest. 2023; 133(13). PMC: 10313378. DOI: 10.1172/JCI166070. View

Monu N, Frey A . Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship. Immunol Invest. 2012; 41(6-7):595-613. PMC: 3701882. DOI: 10.3109/08820139.2012.673191. View

Abe Y, Sakata-Yanagimoto M, Fujisawa M, Miyoshi H, Suehara Y, Hattori K . A single-cell atlas of non-haematopoietic cells in human lymph nodes and lymphoma reveals a landscape of stromal remodelling. Nat Cell Biol. 2022; 24(4):565-578. PMC: 9033586. DOI: 10.1038/s41556-022-00866-3. View

Chapuy B, Stewart C, Dunford A, Kim J, Kamburov A, Redd R . Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018; 24(5):679-690. PMC: 6613387. DOI: 10.1038/s41591-018-0016-8. View

Beguelin W, Popovic R, Teater M, Jiang Y, Bunting K, Rosen M . EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 2013; 23(5):677-92. PMC: 3681809. DOI: 10.1016/j.ccr.2013.04.011. View

Cattoretti G, Pasqualucci L, Ballon G, Tam W, Nandula S, Shen Q . Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell. 2005; 7(5):445-55. DOI: 10.1016/j.ccr.2005.03.037. View

10.

An Y, Liu F, Chen Y, Yang Q . Crosstalk between cancer-associated fibroblasts and immune cells in cancer. J Cell Mol Med. 2019; 24(1):13-24. PMC: 6933413. DOI: 10.1111/jcmm.14745. View

11.

Bhalla K, Jaber S, Nahid M N, Underwood K, Beheshti A, Landon A . Role of hypoxia in Diffuse Large B-cell Lymphoma: Metabolic repression and selective translation of HK2 facilitates development of DLBCL. Sci Rep. 2018; 8(1):744. PMC: 5768748. DOI: 10.1038/s41598-018-19182-8. View

12.

Jiang X, Liang L, Chen G, Liu C . Modulation of Immune Components on Stem Cell and Dormancy in Cancer. Cells. 2021; 10(11). PMC: 8616319. DOI: 10.3390/cells10112826. View

13.

Pan C, Fang Q, Liu P, Ma D, Cao S, Zhang L . Mesenchymal Stem Cells With Cancer-Associated Fibroblast-Like Phenotype Stimulate SDF-1/CXCR4 Axis to Enhance the Growth and Invasion of B-Cell Acute Lymphoblastic Leukemia Cells Through Cell-to-Cell Communication. Front Cell Dev Biol. 2021; 9:708513. PMC: 8558501. DOI: 10.3389/fcell.2021.708513. View

14.

Mondello P, Tadros S, Teater M, Fontan L, Chang A, Jain N . Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. Cancer Discov. 2020; 10(3):440-459. PMC: 7275250. DOI: 10.1158/2159-8290.CD-19-0116. View

15.

Leiva O, Hobbs G, Ravid K, Libby P . Cardiovascular Disease in Myeloproliferative Neoplasms: State-of-the-Art Review. JACC CardioOncol. 2022; 4(2):166-182. PMC: 9270630. DOI: 10.1016/j.jaccao.2022.04.002. View

16.

Chang K, Huang X, Medeiros L, Jones D . Germinal centre-like versus undifferentiated stromal immunophenotypes in follicular lymphoma. J Pathol. 2003; 201(3):404-12. DOI: 10.1002/path.1478. View

17.

Alfaro C, Suarez N, Gonzalez A, Solano S, Erro L, Dubrot J . Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer. 2009; 100(7):1111-9. PMC: 2670006. DOI: 10.1038/sj.bjc.6604965. View

18.

Rodda L, Lu E, Bennett M, Sokol C, Wang X, Luther S . Single-Cell RNA Sequencing of Lymph Node Stromal Cells Reveals Niche-Associated Heterogeneity. Immunity. 2018; 48(5):1014-1028.e6. PMC: 5971117. DOI: 10.1016/j.immuni.2018.04.006. View

19.

Morin R, Mendez-Lago M, Mungall A, Goya R, Mungall K, Corbett R . Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011; 476(7360):298-303. PMC: 3210554. DOI: 10.1038/nature10351. View

20.

Wu F, Yang J, Liu J, Wang Y, Mu J, Zeng Q . Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. Signal Transduct Target Ther. 2021; 6(1):218. PMC: 8190181. DOI: 10.1038/s41392-021-00641-0. View